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The nm23 gene is a reported metastasis suppressor gene. Recent studies have shown that its expression has
tissue specificity. The role of nm23 in human ovarian cancer is still controversial. This study examines the
prognostic significance of nm23 expression in patients with serous ovarian carcinoma. Following comparative
proteomics in 13 fresh frozen ovarian serous cancer tissues with other histological types of ovarian cancers,
validation was performed using immunohistochemistry on clinically well-designed 73 ovarian serous
carcinoma microarray samples that were retrieved from ovarian cancer patients from 1990 to 2003. Statistical
analysis of the results was performed using v2 test, Cox proportional regression, the Kaplan–Meier method and
log-rank test. We found that the expression of nm23 inversely correlated with peritoneal seeding (P¼ 0.009).
However, strong nm23 expression was associated with mortality in patients with ovarian carcinoma in
univariate analysis (P¼ 0.04). Poor prognostic factors of disease-free survival included tumor residue more
than 2 cm (P¼ 0.02), bilaterality (P¼ 0.01) and peritoneal seeding (Po0.01), whereas poor prognostic factors
affecting overall survival included peritoneal seeding (P¼ 0.05). In Kaplan–Meier analysis, strong nm23
immunoreactivity correlates with poor overall survival (P¼ 0.04) but not with poor disease-free survival. In
conclusion, overexpression of nm23 is independently associated with decreased overall survival in patients
with ovarian carcinoma and also significantly correlates with mortality. Nm23 may have a biological function
that leads to poor clinical outcomes in ovarian carcinoma.
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The lethality of serous ovarian carcinomas is
primarily attributed to its advanced stage at the
time of initial diagnosis. It spreads rapidly along the
peritoneum and omentum in approximately 70% of
patients and eventually metastasizes.1 Despite ad-
vances in cytotoxic therapies, only 30% of ovarian
cancer patients survive 5 years after their initial
diagnosis.1–3 Therefore, understanding the molecu-
lar mechanisms regulating the invasion or meta-
static behavior of ovarian cancer will likely have a
significant impact on the outcomes of this devastat-
ing disease and/or on the diagnosis of early-stage
ovarian cancer in patients who are at risk for
subsequent metastatic progression or relapse.
In general, cancer metastasis is an active process
involving multiple, sequential cellular events that
are regulated by numerous genes. In contrast,
ovarian carcinoma metastasis is the result of a
relatively passive process.2 Once a tumor disrupts
the ovarian capsule, it may grow so large that it
extends to and makes contact with the omentum.
Alternatively, cells from the primary tumor may be
transported to the omentum via the peritoneal
fluid.2 Previous genomic studies have shown that
there are little differences in gene expression
profiles between ovarian carcinomas and their
omentum metastases.3
We have previously used a comparative proteomic
approach and various other subtractive and com-
parative methods to examine the gene expression
profiles of ovarian carcinomas.4 The results of these
studies have led to the identification of several
putative biomarkers for ovarian carcinomas. These
candidate genes included nm23, annexin I, protein
phosphatase-1, ferritin, proteasome a-6, N-acetyl
glucosamine kinase (NAGK) and an A6-related
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protein.4 Interestingly, we found that the nm23/NDP
kinase family is typically overexpressed in ovarian
cancers but generally underexpressed in metastatic
cells. In the current study, we use proteomics and
immunohistochemistry to examine the biological
role of nm23 in serous ovarian carcinomas.
Materials and methods
Tissue Specimens and Sample Preparation for 2E
Fresh frozen samples of 13 ovarian serous cancer
tissues were obtained from the Yonsei University
College of Medicine (Table 1). Fresh frozen tissues
were prepared from eight other types of ovarian
cancers (five endometrioid cancers and three muci-
nous cancers) and three samples of kidney, liver,
lung and cervical cancer tissues. All samples were
prepared with the consent of the patients who
donated tissues.
IPG 2D PAGE
IPG dry strips were equilibrated for 12–16 h in a
solution containing 7 M urea, 2 M thiourea contain-
ing 2% 3-[(3-cholamidopropy) dimethylammonio]-
1-propanesulfonate, 1% dithiothreitol (DTT) and
1% pharmalyte. The equilibrated strips were loaded
with 200 mg of sample. Isoelectric focusing (IEF) was
performed at 201C using a Multiphor II electrophor-
esis unit and an EPS 3500 XL power supply
(Amersham Biosciences) following the manufac-
turer’s instructions. For IEF, the voltage was linearly
increased from 150 to 3500 V over 3 h (to allow for
sample entry), then the voltage was held constant at
3500 V with the focusing complete after 96 kVh.
Prior to the second dimension, the strips were
incubated for 10 min in equilibration buffer
(50 mM Tris-Cl, pH 6.8 containing 6 M urea, 2%
SDS and 30% glycerol) with 1% DTT and 2.5%
iodoacetamide. The equilibrated strips were then
inserted onto SDS-PAGE gels (20–24 cm, 10–16%)
that were run using a Hoefer DALT 2D system
(Amersham Biosciences) following the manufac-
turer’s instructions. The 2D gels were run at 201C
for 1700 Vh, then silver stained by the fixing and
sensitization steps with glutaraldehyde being
omitted.
Image Analysis
Quantitative analyses of the digitized images were
performed using the PDQuest software (version 7.0;
BioRad) according to the protocols provided by the
manufacturer. The quantity of each spot was
normalized to the total valid spot intensity. Protein
spots were identified as having a significant varia-
tion in expression if their expression level deviated
by more than twofold relative to the expression level
detected in the control or normal sample.
MALDI-TOF MS
A total of 64 gel spots (nucleus: 31, cytoplasm: 33)
were excised from preparative gels using biopsy
punches and transferred to a 1.5 ml siliconized
Eppendorf tube. The gel spots were destained in
destaining solution containing 100 mM Na2S2O3
(Sigma) and 30 mM K3Fe(CN)6 (Sigma) (V/V, 1:1).
Destained gel pieces were pre-reduced with 100%
acetonitrile (HPLC grade). Then the protein-contain-
ing gel spots were reduced in reduction buffer
(100 mM NH4HCO3 (Sigma) and 10 mM DTT
(Sigma)) for 30 min at 561C and then alkylated in
Table 1 Correlation of nm23 expression and clinical variables
Variables nm23 P-value
Age (years) 0.51
o50 42
Z50 35
Stage 0.06
I, II 53
III, IV 24
Grade 0.12
1–2 30
3 47
Ascites 0.97
Negative 40
Positive 37
CA125 level (U/ml) 0.76
o35 13
35–100 23
4100 41
Residual volume 0.40
Optimal 43
Non-optimal 34
Ovarian bilateralness 0.80
Unilateral 40
Bilateral 37
Peritoneal seeding 0.009a
Negative 60
Positive 17
LN metastasis 0.28
Negative 48
Positive 29
Distant metastasis 0.12
Negative 19
Positive 58
Dead status 0.04a
Alive 25
Dead 52
Recurrent status 0.09
No recurrence 29
Recurrence 48
aStatistical significance (P-value less than 0.05).
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alkylation buffer (100 mM NH4HCO3 (Sigma) and
55 mM iodoacetamide (Sigma)) in the dark for
25 min at room temperature. The gel pieces were
dried using a Speed-Vac. The dried gel pieces were
incubated in ABC buffer (50 mM, pH 8.0) containing
0.1 mg/ml trypsin for 12–16 h at 371C. Following
concentration, the peptide mixture was desalted
using C18ZipTips (Millipore), and the peptides were
eluted in 1–5 ml of 50% ACN/0.1% TFA. An aliquot
of this solution was mixed with an equal volume of a
saturated solution of a-cyano-4-hydroxycinnamic
acid (Sigma) in 50% ACN/0.1% TFA, and 1ml of
this mixture was spotted onto a target plate. The
tryptic peptide mixture was extracted and purified
using a Millipore ZipTip C18 column and concen-
trated using ZipTips (Millipore Corp.). The peptide
samples were cocrystallized with matrix on the
Voyager 96 2 sample plate (P/N V700813) using
0.5 ml matrix (a-cyano-4-hydroxytranscinnamic acid)
and 0.5 ml sample. The samples were then analyzed
using the Applied Biosystems Voyager System 4307
MALDI-TOF Mass Spectrometer (ABI), and des-
Arg1-Bradykinin, Glu1-Fibrinopeptide B and ACTH
(clip 18–39) served as external standards for the
mass calibration.
Clinical Survey for Tested Patients
We examined the medical records and archival
slides in the collection of ovarian serous adenocar-
cinoma in the Gynecologic Oncology Files of Yonsei
University College of Medicine in Korea. We
selected 73 cases of ovarian serous carcinomas since
1990 for further review. Demographics (including
age, sex, tumor site, tumor size, number of tumors,
frequency of tumor recurrence and progression,
associated malignancy and survival time) were
obtained from each patient’s medical records. The
time to recurrence was calculated from the time of
complete response (ie, no evidence of disease) to the
time of the first tumor recurrence upon follow-up
examination. All patients underwent total abdom-
inal hysterectomy with both salpingo-oophorectomy
and pelvic lymphadenectomy, including omentec-
tomy. Patients with advanced ovarian cancer (stage
III/IV) were also given postoperative chemotherapy.
The medical records of all tested patients were
surveyed for the following information: age, stage of
carcinoma, grade, ascites with positive peritoneal
cytology, preoperative serum CA 125, postoperative
tumor residue (2 cm), bilaterality, peritoneal im-
plants, lymph node involvement and distant metas-
tasis. The staging was in accordance with the
standards of the International Federation of Gyne-
cology and Obstetrics. Optimal cytoreduction was
defined as less than 2 cm of postoperative tumor
residue. Disease-specific survival was calculated
using the Kaplan–Meier method, and statistical
analyses were performed using the log-rank test.
The Cox proportional hazards model was used for
multivariate parameter analyses, and a stepwise
model was used to select independent prognostic
factors. A P-value of less than 0.05 was considered
to be statistically significant. All statistical data
were analyzed using SPSS (SPSS ver. 12.0; Chicago,
IL, USA).
Tissue Specimens and Preparation of Samples for
Immunohistochemistry
Seventy-three samples of ovarian serous carcinomas
isolated from 1990 to 2003 were available for
immunohistochemical analysis and censored data.
Recipient blocks were made from purified agar in
3.8 2.2 0.5 cm frames. Using a core needle, 2-mm
holes were made in these recipient blocks, and the
resulting agar cores were discarded. The paraffin
donor blocks were prepared following a thorough
evaluation of the hematoxylin–eosin-stained slides.
Two adjacent areas of a carcinoma from the match-
ing donor blocks were transplanted to the recipient
blocks using a 2-mm core needle. We constructed an
array of samples of adjacent normal areas from these
patients using paraffin-embedded, formalin-fixed
tissue blocks. The recipient blocks were framed in
the same mold that was used for the conventional
paraffin block. Paraffin was then added to the frame.
Consecutive 4-mm thick sections were cut from the
recipient blocks using an adhesive-coated slide
system (Instrumedics Inc., Hackensack, NJ, USA).
The 4-mm sections were placed on silane-coated
slides, deparaffinized, immersed in phosphate-buf-
fered saline (PBS) containing 0.3% (v/v) hydrogen
peroxide and processed in a microwave oven (in
10 mM sodium citrate buffer, pH 6.5, for 15 min at
700 W). After blocking with 1% (w/v) bovine serum
albumin in PBS containing 0.05% (v/v) Tween 20 for
30 min, the slides were incubated overnight at 41C
with nm23. Immunoperoxidase staining was per-
formed using the streptavidin–biotin peroxidase
complex method (LSAB universal kit; DAKO,
Carpinteria, CA, USA). As negative controls, sub-
type-matched normal mouse IgGs were used. The
final reaction product was visualized with the
addition of 0.03% (w/v) of 3,30-diaminobenzidine
tetrachloride for 5–20 min. Strong cytoplasmic
staining was considered a positive result. Immunos-
taining was graded and scored as follows: 0
(no staining), 1þ (weak, diffuse staining) and 2þ
(strong, diffuse staining).
Database Analysis
The MS-Fit (UCSF Mass Spectrometry, ProteinPros-
pector v 4.0.5) was used for protein identification
via peptide mass fingerprinting. The spectra were
calibrated using trypsin autodigestion ion peaks m/z
(842.510, 2211.1046) as internal standards. Swiss-
Prot. 10.30.2003 and NCBInr. 10.21.2003 were used
as databases.
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Results
Proteome Analysis of Human Ovarian Tumor Tissues
The 2D-E protein patterns were quantified and
matched. To select protein variations, the protein
patterns of the tumor and control samples were
divided into two classes, and the quantities of all of
the detected spots in each class were compared
using the PDQuest software (v 7.0). To compare the
differences in protein expression specifically in
ovarian tumors, we included data from other
tumors, including lung cancer, hepatoma, cervical
cancer and renal cell carcinoma. The PMF maps
were then obtained using MALDI-TOF MS. These
data were used to search MS-Fit (ProteinProspector
v 4.0.5), and the identity of protein was determined
by comprehensively considering the corresponding
experimental MOWSE score, the number of matched
peptides Mp PI and the sequence coverage. Compar-
isons of spot expressions in the tissues analyzed
revealed that all of the tumors tested (kidney, lung,
uterine cervix and ovary), with the exception of
hepatoma, had significantly higher nm23 expression
than their corresponding normal tissues. The nm23
was more highly expressed in serous and endome-
trioid types of ovarian cancer and was more weakly
expressed in mucinous types of ovarian cancer
(Figure 1).
Clinical Correlation of nm23 Immunoreactivity
Ovarian serous carcinomas had positive immuno-
reactivity for nm23 (Figure 2). The clinical correla-
tion with nm23 expression is illustrated in Table 1.
The strong expression of nm23 was inversely related
to the presence of peritoneal implants. Specifically,
60% of the patients with strong nm23 expression
had no peritoneal implants, whereas only 27% of
those patients had peritoneal implants (P¼ 0.009).
In addition, a stronger level of nm23 expression was
detected in patients with higher stages (III/IV) of
disease than in those with lower stages (I/II) of the
disease, but these differences are not significant
(P¼ 0.06). Nm23 overexpression was significantly
more frequent in dead patients of ovarian cancer
than in alive patients (54 vs 28%; P¼ 0.02).
Survival Analysis and nm23 Expression in Ovarian
Cancer
Multiple parameters have been used to predict the
biological behavior of ovarian serous cancer by
univariate (Table 2) and multivariate survival ana-
lyses (Table 3). In multivariate analysis, poor
prognostic factors of disease-free survival included
tumor residue more than 2 cm (P¼ 0.02), bilaterality
(P¼ 0.01) and peritoneal seeding (Po0.01), whereas
poor prognostic factor affecting overall survival
included peritoneal seeding (P¼ 0.05). In Kaplan–
Meier analysis, strong nm23 immunoreactivity
correlates with poor overall survival (P¼ 0.04) but
not with poor disease-free survival (Figure 3).
Discussion
Using proteomics and immunohistochemistry, we
discovered that nm23 overexpression correlates
with distant metastasis and reduced disease-free
and overall survival in ovarian serous carcinoma,
whereas reduced nm23 expression is strongly
Figure 1 Comparative quantification in 2D-E protein spot. This spot was confirmed to be nm23A expressed in isoform A using MS-Fit.
The above figure represents legend of each row and column corresponding to the below figure. Notice the strongest spot in ovarian serous
carcinoma relative to endometrioid and mucinous tumors. There is an increase in nm23 expression in cervical cancer, lung cancer and
renal cell carcinoma, whereas there is a decrease in nm23 expression in hepatoma. Cx, cervical cancer; Kc, kidney cancer; Lu, lung
cancer; Lv, liver cancer; N, normal; Ov, ovary cancer; T, tumor. Each roman number in the Cx (cervical cancer) represents FIGO stage.
ET,endometrioid carcinoma; MT, mucinous carcinoma; ST, serous carcinoma; STb, serous tumor of borderline malignancy.
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associated with peritoneal implants. On the basis of
these results, we propose that the differential
expression of nm23 affects its biological role. The
association of nm23 overexpression with distant
metastasis is surprising, given the traditional view
of nm23 as a metastasis suppressor gene. Although
this finding is contradictory, it is meaningful
because it represents the first analysis of the role
of nm23 in ovarian cancer tissue samples using a
proteomics approach involving well-designed ovar-
ian serous cancer patients with a long-term follow-
up period up to 13 years. These proteomics results,
which were confirmed by immunohistochemistry,
support our hypothesis that nm23 overexpression is
a tumor progression marker. Furthermore, we found
a greater overexpression of nm23 in serous carcino-
mas than in mucinous tumors. This result contra-
dicts previous reports of nm23 immunoexpression
in ovarian mucinous tumors.5 This discrepancy is
likely due to the different interpretations and
methods used in the studies. However, it should
be noted that the immunohistochemistry of nm23
should be interpreted cautiously as positive staining
is restricted only to strong, diffuse expression not to
focal, diffuse weak staining.6
The murine nm23 cDNA was first identified by
differential colony hybridization, which demon-
strated its elevated expression in nonmetastatic
murine K-1735 melanoma cell lines (nonmetastatic
clone 23) and its reduced expression in a highly
metastatic paired cell line.7 In humans, there are two
nm23 genes, nm23-H1 and nm23-H2, that are
located on chromosome band 17q–21.3. These genes
encode human nucleoside diphosphate kinase A
and B, respectively,8 and share significant homology
with the Drosophila development gene awd and the
Dictostelium NDP kinase gene.9 Expression levels of
nm23 have been widely reported in human tumor
cohorts.10 Although the expression of nm23 is not a
universally independent predictive or prognostic
factor for ovarian cancer, both metastasis suppres-
sion and disease progression have been linked to
elevated nm23-H1 gene expression in different types
of human tumors. As the simple overexpression of
nm23 is a poor prognostic factor, it is possible that
nm23 plays some tissue-specific roles and that
different mechanisms regulating its overexpression
Figure 2 Immunohistochemical results of nm23 in ovarian serous adenocarcinomas. (a) Negative immunostaining for nm23. (b) Focal,
weak staining for nm23, graded as 1þ . (c) Intense, strong immunoreactivity for nm23, graded as 2þ (which is regarded as a true positive
result).
Table 2 Univariate survival analysis of nm23 overexpression in
ovarian serous carcinoma
Variables Median survival (years) HR (95% CI) P-value
Nm23 1.30 (1.01–1.68) 0.04*
Negative Not reached
Positive 4.50
Disease-free survival (years) HR (95% CI) P-value
Nm23 1.17 (0.96–1.42) 0.11
Negative 2.00
Positive 1.25
*Statistical significance (P-value less than 0.05).
Table 3 Multivariate survival analysis of nm23 overexpression in
ovarian serous carcinoma
Variables HR (95% CI) P-value
Overall survival
Peritoneal seeding 47.60 (1.04–2421.7) 0.05a
Disease-free survival
Residual volume: non-optimalb 2.09 (1.13–3.87) 0.02a
Ovarian bilateralness 3.36 (1.31–8.62) 0.01a
Peritoneal seeding 3.87 (1.74–8.62) o0.01a
a
Statistical significance.
b
Non-optimal: residual volume Z2 cm.
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are involved in the development of certain types of
tumors. Many studies have suggested an association
between low nm23 expression and tumor aggres-
siveness and patient mortality in hepatoma,10 head
and neck cancer,11,12 melanoma13 and breast can-
cer.14,15 Despite the widely accepted data on reduced
nm23 expression and metastatic aggressiveness in
breast cancer, it still does not represent an indepen-
dent prognostic factor.6 Furthermore, there has been
no correlation or positive association between nm23
expression and tumor aggressiveness reported in
neuroblastoma,16 genitourinary tract cancers (in-
cluding testis, prostate and endometrium),6 kidney
cancer, thyroid cancer,17 pancreatic cancer18 or lung
cancer.19 The role that the nm23-H1 gene plays in
ovarian carcinoma has not yet been determined. The
correlation between nm23 expression and ovarian
cancer was first examined in a cohort study in
1994.20 This study demonstrated that the over-
expression of both nm23-H1 and nm23-H2 was
associated with the progression of malignant tumors
rather than with the progression of normal ovary or
benign tumors. Subsequent studies, using other
methods such as northern blotting or immunohis-
tochemistry, confirmed nm23 as a tumor progression
marker.21–24 One report used immunohistochemistry
to reveal a connection between nm23-H1 over-
expression and both survival advantage and greater
response to chemotherapy in 106 patients with
advanced ovarian cancer. In this study, there were
more nm23-H1-positive patients without lymph
node involvement (70%) than nm23-H1-positive
patients with lymph node involvement (40%).25
Later studies using allelic deletions of 17q revealed
that an extremely high frequency of LOH (73–93%)
had no impact on the prognosis or metastatic
behavior of ovarian cancer.21,22
Despite extensive research, the biological mechan-
isms by which elevated nm23 expression suppresses
metastasis are still not understood. The interaction
between nm23-H1 and Ksr has been characterized,26
and it was shown that mutations that inactivate Ksr
suppress the phenotypic effects of activated Ras.27 It
is known that the overexpression of nm23-H1
results in diminished Map kinase activation, which
is required for higher histidine protein kinase
activity.28 Several characterized intracellular func-
tions of nm23, namely microtubule assembly and
disassembly,29 signal transduction,30 transcription
regulation31 and cellular adhesion,32 are known to
influence certain metastatic processes.
In other biological contexts, increased nm23
expression correlates with aggressive disease. In
these cases, the increased expression is associated
with nm23 mutations,16,33 heterogeneity of phos-
phorylated isoforms,34 association with GTPase-
activating proteins35 and NDP kinase activity.36
The nm23 mutations have seldom been detected in
ovarian cancer. In a stratified univariate analysis
and a complete multivariate model of 247 ovarian
cancer patients, it was found that nm23 overexpres-
sion was an independent predictor of an ominous
outcome.37 Schneider et al9 demonstrated that nm23
overexpression had a negative impact on prognosis
and that the nm23 overexpression was to a wild-
type nm23 gene rather than to mutant variants. It is
possible that nm23-H1 functions similarly to nm23-
H2, which has been shown in vitro to initiate
transcription of c-myc,38 or another related onco-
gene associated with more malignant phenotypes in
human ovarian cancer.
The present study to document that overexpres-
sion of nm23 was significantly fewer in case of
peritoneal seeding (27 vs 60%) represents that nm23
expression suppresses peritoneal seeding. Regard-
less of peritoneal seeding suppression, however,
nm23 expression has shown that it was significantly
associated with poor overall survival.
In conclusion, elevated nm23 protein expression
is an independent prognostic marker for diminished
overall survival in patients with ovarian serous
carcinoma.
Figure 3 Kaplan–Meier survival with respect to nm23 expression. (a) On overall survival analysis, nm23 overexpression was
significantly associated with poor survival (P¼0.04). (b) The overexpression of nm23 was significantly associated with poor progression-
free survival (P¼0.03). The continuous line represents the low expression of nm23, and the dotted line represents the high expression
of nm23.
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